Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05970913 | PET-CT Predicting Lymph Nodes Metastasis | active not recruiting | — | 280 | Fudan UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05306509 | Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology(NiCE) | recruiting | N/A | 120 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07480694 | Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC | not yet recruiting | — | 400 | Fudan UniversityOTHER | 0 | Mar 18, 2026 | clinicaltrials |
| NCT06730204 | Standardized Nutritional Management of Pediatric Patients With Solid Tumors | recruiting | N/A | 400 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07469241 | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.(FUTURE-3) | not yet recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07469267 | Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases(RELAX) | recruiting | N/A | 1,608 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471776 | Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07466927 | Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06775743 | ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07450040 | Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma | enrolling by invitation | — | 60 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07445022 | RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma | recruiting | Phase 4 | 110 | Fudan UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06524167 | RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer | recruiting | — | 80 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06554652 | Selective Neck Dissection Versus Modified Neck Dissection in PTC | recruiting | Phase 3 | 250 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06558981 | Adjuvant Radiotherapy in High Risk Locally Advanced DTC | recruiting | Phase 3 | 124 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06583837 | Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma | active not recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07193186 | Anlotinib and Benmelstobart in DTC | not yet recruiting | Phase 2 | 23 | Fudan UniversityOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07438418 | An Observational Study on Gastric Cancer in High-risk Individuals | not yet recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04761185 | Raltitrexed in HIPEC | completed | Phase 1 | 30 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06896370 | An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori | recruiting | — | 3,000 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06943781 | Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection | recruiting | — | 15,000 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06943794 | Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial | not yet recruiting | N/A | 4,824 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06943807 | Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis | recruiting | — | 15,000 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07434284 | Exploratory Clinical Study of cCTL in Combination With Immunotherapy for Advanced Gynecologic Malignancies | recruiting | Early Phase 1 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07423611 | ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer(RACE) | not yet recruiting | Phase 2 | 388 | Fudan UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07419867 | A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI | not yet recruiting | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07410559 | Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer | not yet recruiting | Phase 2 | 189 | Fudan UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07418866 | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Fudan UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07418879 | A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC | not yet recruiting | N/A | 25 | Fudan UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07412054 | Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC(BLP-HCC) | not yet recruiting | Phase 2 | 234 | Fudan UniversityOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07411443 | AI-Enhanced Imaging in Population Breast Cancer Screening | recruiting | N/A | 16,000 | Fudan UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06670495 | HPV Genotype Attribution and Disease Burden of Anal Cancer in China | recruiting | — | 300 | Fudan UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407517 | Adjuvant Intensification for LAR(POLARIS) | not yet recruiting | Phase 3 | 904 | Fudan UniversityOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06943235 | Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07403877 | Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer(TORCH-OPTIMA) | not yet recruiting | Phase 2 | 114 | Fudan UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07398937 | Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC(ECTOP-1036) | recruiting | Phase 2 | 116 | Fudan UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07400354 | The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota | recruiting | — | 300 | Fudan UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05673824 | Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. | completed | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07394218 | ctDNA-guided Treatment Decision-making | recruiting | Phase 2 | 122 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07394244 | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05142709 | Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC. | completed | — | 1,197 | Fudan UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389876 | Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma(G/GEJ) | recruiting | — | 250 | Fudan UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391007 | Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases | not yet recruiting | — | 200 | Fudan UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07382687 | Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype | not yet recruiting | Phase 3 | 248 | Fudan UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07381738 | Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07368543 | Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer(STORM) | not yet recruiting | Phase 2 | 216 | Fudan UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07370337 | Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal | recruiting | Phase 2 | 50 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07371273 | Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure(BRIGHT) | not yet recruiting | Phase 2 / Phase 3 | 268 | Fudan UniversityOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07362836 | Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS) | not yet recruiting | Phase 3 | 224 | Fudan UniversityOTHER | 0 | Jan 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials